ArticleESC heart failure2025
Real-world use of guideline-directed therapy for heart failure: Insights from the Danish Heart Failure Registry.
Article in ESC heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Structured Functional Assessment Pathway and Pharmacological Optimization During Cardiovascular Rehabilitation in Chronic Heart Failure: A Retrospective Tertiary Center Study.Life (Basel, Switzerland) · 2026Article
- Characteristics and outcomes of patients with heart failure and reduced left ventricular ejection fraction in relation to sodium-glucose cotransporter-2 inhibitor treatment: real-world data from the multicentre HClinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Real-world use of guideline-directed therapy for heart failure: Insights from the Danish Heart Failure Registry.ESC heart failure · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
aimsWe aimed to assess real-world implementation of guideline-directed medical therapy (GDMT) for heart failure (HF) with reduced ejection fraction (HFrEF) and its association with mortality and hospitalization.
methodsWe analysed 46 816 incident HFrEF patients from the Danish Heart Failure Registry (2008-2022). We examined the utilization of GDMT-renin-angiotensin system inhibitors (RASi), beta-blockers, mineralocorticoid receptor antagonists (MRAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2i)-at 4, 8 and 12 weeks of follow-up according to the European Society of Cardiology guidelines within the intervals 2008-2011, 2012-2015, 2016-2020 and 2021-2022. Using Cox regression, we assessed the associations between GDMTs [none (reference), 1-2 GDMTs, and 3-4 GDMTs] initiated at 4, 8 and 12 weeks and 1 and 3 year mortality (all-cause and cardiovascular) and hospitalization (all-cause and HF).
resultsBetween 2008-2011 and 2021-2022, RASi utilization at 4 weeks of follow-up was 93.2% and 93.7%, respectively, and at 12 weeks of follow-up, 97.2% and 97.8%, respectively. Beta-blocker use was 81.1% and 78.2% at 4 weeks and 89.6% and 90.4% at 12 weeks of follow-up while MRA utilization was 27.2% and 34.6% at 4 weeks and 32.6% and 52.2% at 12 weeks of follow-up. The SGLT2i use at 4 weeks increased from 0.0% to 21.3%, and at 12 weeks of follow-up from 3.2% to 35.8% between 2016-2020 and 2021-2022. The initiation of GDMTs at 4 weeks of follow-up was associated with lower adjusted hazard ratios (HRs) [95% confidence intervals (CI)] for 1 year all-cause mortality [1-2 GDMTs: 0.73 (95% CI: 0.61-0.86), 3-4 GDMTs: 0.65 (95% CI: 0.55-0.78)], 3 year all-cause mortality [1-2 GDMTs: 0.75 (95% CI: 0.66-0.86); 3-4 GDMTs: 0.67 (95% CI: 0.59-0.76)] and 3 year cardiovascular mortality [1-2 GDMTs: 0.74 (95% CI: 0.62-0.89); 3-4 GDMTs: 0.72 (95% CI: 0.59-0.87)]. Lower adjusted HRs were also observed for 1 year all-cause hospitalization [1-2 GDMTs: 0.80 (95% CI: 0.75-0.86); 3-4 GDMTs: 0.78 (95% CI: 0.73-0.84)] and 3 year all-cause hospitalization [1-2 GDMTs: 0.77 (95% CI: 0.72-0.83); 3-4 GDMTs: 0.77 (95% CI: 0.71-0.82)].
conclusionsWe demonstrated high use of RASi and beta-blockers and rising use of MRA and SGLT2i, reflecting rapid adaption to guidelines changes in incident HFrEF patients. Early GDMT initiation was associated with lower 1 and 3 year mortality and all-cause hospitalization. Upfront treatment with GDMT, according to the latest guidelines, is crucial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.